Trial results for a study investigating atezolizumab in conjunction with digital health solutions for cancer patients (NCT05694013) were posted on ClinicalTrials.gov on 2025-10-22. This Phase 2/3 study, which was subsequently terminated, aimed to evaluate the clinical impact and utility of digital health solutions on health outcomes and healthcare resource utilization.
Background
The study investigated the use of atezolizumab, a systemic anti-cancer treatment, in combination with digital health solutions. The trial aimed to understand the impact of these solutions on health outcomes and healthcare resource utilization in individuals receiving cancer treatment.
Trial design
The Phase 2/3 study (NCT05694013) was designed to evaluate the clinical impact and utility of digital health solutions in participants receiving systemic treatment for cancer. The trial enrolled 49 participants and involved interventions with atezolizumab sc. The study compared outcomes between an Atezolizumab Regimen group and an Atezolizumab Regimen + DPM group. The trial was ultimately terminated.
Key results
Results were posted for changes from baseline in Global Health Status Score/Quality of Life Score (GHS/QoL) from the European Organisation for Research and Treatment of Cancer (EORTC) Item Library 6 (IL6) GHS/QoL. Median scores observed for the Atezolizumab Regimen group included 66.67 Units on a scale, 62.50 Units on a scale, 66.67 Units on a scale, 62.50 Units on a scale, and 75.00 Units on a scale. For the Atezolizumab Regimen + DPM group, median scores included 66.67 Units on a scale, 58.33 Units on a scale, 70.83 Units on a scale, 83.33 Units on a scale, and 83.33 Units on a scale.
Additionally, for the outcome of 'Change From Baseline in the EuroQol 5-Dimension, 5-Level Questionnaire (EQ-5D-5L) Visual Analogue Scale (VAS) Instrument', the Atezolizumab Regimen group showed a median score of 71.00 Units on a scale.
What this means
The posted results provide median quality of life scores for participants receiving atezolizumab with or without digital health solutions. Given the termination of the study and the absence of comparative statistical analyses or primary endpoint data, the practical implications of these specific median scores are limited in determining the overall clinical impact or utility of digital health solutions in this context.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for study NCT05694013, titled 'Clinical Impact and Utility of Digital Health Solutions in Participants Receiving Systemic Treatment in Clinical Practice,' were posted on 2025-10-22 on clinicaltrials.gov.